Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian share markets remain weak
Tue, 2 Jul 11:30 am

Indian share markets have remained weak in the last two hours of trade. Consumer durables and healthcare are leading the pack of winners while capital goods and realty are facing the maximum selling pressures.

The BSE-Sensex is down by 48 points and NSE-Nifty is down by 21 points. BSE Mid Cap index is down by 0.1% while the BSE Small Cap index is up by 0.2%. The rupee is trading at 59.42 to the US dollar.

Indian Pharma shares are trading on a mixed note with Panacea Biotech and Fresenius Kabi Onco leading the gains while Dishman Pharma and Indoco Remedies are leading the losses. According to a leading financial news medium, Drug firm, Lupin is planning to expand its footprint in Latin America. It will preferably acquire companies in Brazil, Mexico, Argentina and Chile. All these acquisitions will be financed by internal accruals. The pharma major has a history of acquiring firms that suit its business plans, the last acquisition being Japan's speciality injectables company I'rom Pharmaceutical in 2011.The Mumbai-based Company is also targeting to buy brands in key therapeutic areas. In this regard, it is in talks with several companies in the US.

Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa. Lupin's share is trading up by 2.5%.

Engineering shares are trading on a mixed note with Praj Industries Ltd and Emco Ltd leading the gains while BGR Energy and Jain Irrigation are leading the losses. According to a leading financial news medium, Larsen & Toubro's (L&T) subsidiary, L&T Construction has secured new orders worth Rs 30.6 bn across various business segments in June 2013. The Company's Building and Factories Business has secured orders worth Rs 18.1 bn for the construction of an office space, residential building and a hospital from customers across the country. The Water and Renewable Energy Business has bagged orders worth Rs 6.3 bn. In the Power Transmission and Distribution Business, orders worth Rs 4.4 bn have been received from the Delhi Metro Rail Corporation. Additional orders have also been received in domestic and international markets of ongoing projects. New orders worth Rs 1.8 bn have been secured in Heavy Civil infrastructure and Metallurgical and Material Handling Businesses from various ongoing projects. L&T's share is trading down by 1.2%

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets remain weak". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.